Key result
All pharmacoeconomic evaluations of targeted PAH therapies use Markov models based on WHO functional class.
Why the study?
Targeted therapies improve survival and quality of life in pulmonary arterial hypertension but impose financial burden, warranting a review of decision-analytical models to guide future pharmacoeconomic research.
Systematic Review (n=13)
This systematic review highlights that Markov models based on WHO functional class are standard for PAH pharmacoeconomic evaluations, but future studies need better quality of life data across disease severities.
Markov models based on WHO functional class remain standard for PAH cost-effectiveness analyses; future studies require improved quality-of-life data across severities.
BACKGROUND: The implementation of targeted drug therapy results in a significant improvement in both survival rates and quality of life among patients diagnosed with pulmonary arterial hypertension (PAH), concurrently imposing a greater financial burden on them. The use of pharmacoeconomic evaluation based on decision-analytical models is extensively employed in the rational allocation of healthcare resources. OBJECTIVES: The present study conducted a systematic review of the literature on the pharmacoeconomic evaluation of drugs for treating PAH, with a focus on summarizing the composition and sources of parameters in decision-analytical models. This study aims to provide methodological guidance for future economic research. METHODS: The review was conducted across six databases (PubMed, Embase, the Cochrane Library, CNKI, VIP, WanFang Data) and two health technology assessment agency websites (NHS EED, INAHTA). The characteristics of each study and the compositional details of the decision-analytical models are extracted. RESULTS: In total, 13 published studies were included. The pharmacoeconomic evaluation methods employed in the studies included cost-effectiveness analysis (CEA) and cost-utility analysis (CUA). The decision analysis models employed in all 13 studies were Markov models. The models were all constructed on the basis of the World Health Organization (WHO) functional class, with variations in parameter settings and sources. CONCLUSIONS: All 13 Markov models provided useful insight into PAH modeling. Future research in this field can employ these research methods according to diverse research objectives. The utility values were derived from a single source; therefore, future studies should evaluate the quality of life in patients with PAH across varying disease severities.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2025) conducted a systematic review in Pulmonary arterial hypertension (n=13). Targeted therapies was evaluated on Composition and sources of parameters in decision-analytical models. A systematic review of 13 studies found that all employed Markov models based on WHO functional class for the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: